Lepodisiran Phase I Trial
February 7, 2024 | Steven Nissen and C. Michael Gibson discuss the efficacy and safety of lepodisiran, an extended-duration siRNA meant to reduce Lp(a). |
TCTMD Talking Points
2024-02-07T15:00:00Z
New at TCTMD? Register today!
Enter the email you used to register to reset your password.